Management Strategies for CLN2 Disease

Стратегии ведения пациентов с болезнью CLN2
Jonathan W. Mink, Boris Zernikow, Nicola Specchio, Szilárd Kiss, John A. Lawson, Katherine B. Sims, Jessica L. Cohen-Pfeffer, Jonas Denecke, Heather Adams, Charlie Fairhurst, Meral Topçu, Angela Schulz, Martin E. G. Blohm, Emily de los Reyes, Norberto Bernardo Guelbert, Miriam Nickel, Ina von Löbbecke, Ruth Elizabeth Williams, Lenora M. Lehwald, Renée Shediac, Kristen Drago, Margie Frazier, Annamaria Kofler, Mary-Anne Leung, Svetlana V. Mikhaylova, Andrea West
2017-02-04

CLN2 diseasemultidisciplinary managementneuronal ceroid lipofuscinosis type 2pediatric palliative caretripeptidyl peptidase 1 deficiency
CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death. No management guidelines exist and there is a paucity of published disease-specific evidence to inform clinical practice, which currently draws upon experience from the field of childhood neurodisability. Twenty-four disease experts were surveyed on CLN2 disease management and a subset met to discuss current practice. Management goals and strategies are consistent among experts globally and are guided by the principles of pediatric palliative care. Goals and interventions evolve as the disease progresses, with a shift in focus from maintenance of function early in the disease to maintenance of quality of life. A multidisciplinary approach is critical for optimal patient care. This work represents an initial step toward the development of consensus-based management guidelines for CLN2 disease.
1
A survey of 24 disease experts found globally consistent management goals and strategies guided by pediatric palliative care principles.
2
CLN2 disease lacks formal management guidelines and disease-specific evidence, so current care relies largely on childhood neurodisability experience.
3
Management priorities evolve with disease progression, shifting from preserving function early to maintaining quality of life later.
4
Multidisciplinary care is identified as critical for optimal management of CLN2 disease.
5
The findings provide an initial foundation for developing consensus-based management guidelines for CLN2 disease.

CLN2 disease (neuronal ceroid lipofuscinosis type 2)

disease management goals and strategies across the progression of CLN2 disease

Publication Details
Publication Date
2017-02-04
Journal
Publisher
ISSN
Cited by
126
Access Type
Author Information
Authors
Jonathan W. Mink
Boris Zernikow
Nicola Specchio
Szilárd Kiss
John A. Lawson
Katherine B. Sims
Jessica L. Cohen-Pfeffer
Jonas Denecke
Heather Adams
Charlie Fairhurst
Meral Topçu
Angela Schulz
Martin E. G. Blohm
Emily de los Reyes
Norberto Bernardo Guelbert
Miriam Nickel
Ina von Löbbecke
Ruth Elizabeth Williams
Lenora M. Lehwald
Renée Shediac
Kristen Drago
Margie Frazier
Annamaria Kofler
Mary-Anne Leung
Svetlana V. Mikhaylova
Andrea West
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%